This report provides an overview of therapies currently in clinical development for Parkinson’s disease. The program status and result information include updates until March 2023. Brief rationale and progress in several key areas of therapeutic interest are described along with a more detailed listing of specific therapies, current development status and, where appropriate, information about MJFF support (funding or non-funding). MJFF monitors numerous information sources to assess the therapeutic pipeline for Parkinson’s disease. This report is not comprehensive of every approach or intervention being developed today, but represents treatments identified by MJFF research staff as important for monitoring given significance to the Parkinson’s community and for understanding MJFF role and impact. The report is mostly focused on pharmacological and biologic therapies, while approaches such as exercise, alternative therapies and behavioral interventions are generally not included. In addition, clinical programs on neuromodulation and technology- enabled therapies represent active MJFF funded programs and are not a full listing of all approaches currently in development. The report will be updated and distributed on an annual basis. Information in this report is not confidential and is intended only as a guide for communicating pipeline progress with our community stakeholders. Any errors or omissions are not intentional.

Q1 2023 / March 2023